Plain-English translation of NCT06983028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing , a new medication designed to treat several autoimmune kidney diseases—including IgA nephropathy, membranous nephropathy, and other conditions that damage the kidney's filtering units. Researchers want to see if this medication is safe and effective at reducing protein loss in urine and slowing kidney damage in patients who have not fully responded to current standard treatments.
Current treatments don't work well enough for many patients with these autoimmune kidney diseases, and some people develop resistant forms that keep getting worse. This medication targets a different part of the immune system, offering hope for patients who need better options.
You likely qualify if…
You likely don't qualify if…
You will continue taking your current kidney disease medications while also receiving the new medication as part of the trial. The study involves multiple clinic visits where doctors will check your kidney function through blood and urine tests, monitor your blood pressure, and watch for any side effects. The trial is designed to follow participants over time to see how well the medication works at reducing protein in the urine and protecting kidney function.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Vera Therapeutics, Inc.
Enrollment target
~250 participants
Started
July 2025
Primary completion
November 2027
Age range
2 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vera Therapeutics, Inc. Clinical Trials Information
Vera Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.